CME Presentations

Alpha 1


Presentations


Speakers

  • Robert Sandhaus, MD, PhD, FCCP

    Robert Sandhaus, MD, PhD, FCCP

    Robert Sandhaus, MD, PhD, FCCP

    Pulmonologist

    Robert Sandhaus, MD, PhD, FCCP, joined the UCSF medical faculty and subsequently the medical faculty at the University of Colorado School of Medicine where he founded the Alpha-1 Antitrypsin Deficiency Program at National Jewish Health where he remains its director. His early research focused on the role of white blood cell proteases in the prevention and promotion of lung disease. This work led to a special clinical interest in patients with the genetic deficiency of alpha-1 antitrypsin. More recently he has been involved in evaluating the lung function of patients with Osteogenesis Imperfecta. Dr. Sandhaus currently serves as a member of the OI Foundation’s MAC. In addition, he is the Senior Medical Director and Executive Vice President of AlphaNet and AlphaNet Canada.
  • James Stoller, MD, MS

    James Stoller, MD, MS

    James Stoller, MD, MS

    Pulmonary/Critical Care Physician

    James Stoller, MD, MS, is a pulmonary/critical care physician at the Cleveland Clinic, Chairman of the Cleveland Clinic Education Institute, and Head of Respiratory Therapy at the Cleveland Clinic. He holds the Jean Wall Bennett Professorship and the Samson Global Leadership Academy Endowed Chair at the Cleveland Clinic Lerner College of Medicine. Dr. Stoller holds a MS in organizational development and serves as adjunct Professor of Organizational Behavior at the Weatherhead School of Management of Case Western Reserve University. His main areas of interest in pulmonary/critical care regard alpha-1 antitrypsin deficiency, COPD, and the delivery of respiratory care services and in organizational behavior regard the impact and organization of physician leadership development.

CME Information

NJH LogoPQH Logo

Are you Missing the Hidden Genetic COPD in Your Patients? A Direct Approach to Testing for Alpha-1 Antitrypsin Deficiency

Program Title: Are you Missing the Hidden Genetic COPD in Your Patients? A Direct Approach to Testing for Alpha-1 Antitrypsin Deficiency
Program Date: November 18 at 8:30AM ET

Program Title: Knowing the Genes of Your COPD Patients Could Change Outcomes
Program Date: November 18 at 9:30AM ET

Program Overview

Chronic obstructive pulmonary disease (COPD), one of the major health care problems impacting global health, is a major cause of death in many countries with an incidence that continues to increase due to smoking and the aging population. Alpha 1-antitrypsyn deficiency (AATD) is a disorder characterized by low serum and lung levels of alpha 1-antitrypsyn (AAT). Between 1%-5% of patients with diagnosed COPD are estimated to have AATD; however, the real prevalence is likely underestimated as AATD is severely underdiagnosed and, despite evidence of survival improvement among patients with AATD on augmentation therapy, testing rates for AAT remain dismally low.

As clinicians on the frontlines of care for patients with COPD, pulmonologists and primary care physicians must be prepared to appropriately assess and engage patients with effective shared decision-making strategies. Join a panel of clinician experts for back-to-back educational sessions on the need for appropriate AATD testing. Session 1, “Are You Missing the Hidden Genetic COPD in Your Patients? A Direct Approach to Testing for Alpha-1 Antitrypsin Deficiency” is designed for pulmonology specialists. Session 2, “Knowing the Genes of Your COPD Patients Could Change Outcomes,” is geared toward primary care clinicians.

Panelists in both sessions will explore guideline-based genetic testing for patients with COPD, evidence-based therapeutic considerations based on testing results, and management implications for patients and their families. Strategies to address common concerns related to testing, such as how to order tests, overcoming barriers, and patient education on the benefits and role of testing, will also be shared.

Faculty
Robert A. Sandhaus, MD, PhD, FCCP
Professor, Division of Pulmonary, Critical Care, and Sleep Medicine
National Jewish Health
Clinical Director, Alpha-1 Foundation
Medical Director, AlphaNet

James K. Stoller, MD, MS
Professor and Chairman, Education Institute
Staff, Respiratory Institute
Cleveland Clinic

Learning Objectives

Session 1: Are you Missing the Hidden Genetic COPD in Your Patients? A Direct Approach to Testing for Alpha-1 Antitrypsin Deficiency

  • Summarize the true incidence of alpha-1 antitrypsin deficiency (AATD) and its contribution to obstructive pulmonary disease, such as COPD
  • Describe the genetic underpinning of AATD, its impact on the spectrum of AATD disease manifestations, and its relationship with emphysema risk
  • Recognize patient presentations who should be genetically tested for AATD
  • Explain the implications of genetic testing results on a patient’s management and counseling of blood relatives

Session 2: Knowing the Genes of Your COPD Patients Could Change Outcomes

  • Summarize the role of AATD in the development and progression of obstructive pulmonary disease, such as COPD
  • Describe the genetic underpinning of AATD, its relationship with emphysema risk, and implications for genetic testing to confirm its diagnosis
  • Apply current guideline recommendations to the recognition of patients with respiratory conditions who should be tested for AATD

Target Audience

The target audience for this activity are pulmonologists and primary care physicians who treat COPD.

Commercial Support:

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Conflict of Interest:

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.

All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.

Faculty Disclosures:

Robert A. Sandhaus, MD, PhD, FCCP, discloses he is on an advisory board for Grifols, CSL Behring, Takeda, AstraZeneca, Kamada, Mereo, Vertex, Dicerna, Arrowhead, Inhibrx, and Korro Bio. He has also received research grants from Vertex and Mereo.

James K. Stoller, MD, MS discloses he is a consultant for Grifols, CSL Behring, Takeda, Vertex, Korro, Arrowhead, Dicerna, InhibRx, 4DMT, Biobridge, and Insmed.

Planners and Reviewer Disclosures:

Meghan Brenner, MA has no relevant financial relationships to disclose.
Carole Drexel, PhD has no relevant financial relationships to disclose.
Bridget Griffin has no relevant financial relationships to disclose.
Jaimee Harris-Gold has no relevant financial relationships to disclose.
Andrea Harshman, MHA, CHCP, CMP-HC has no relevant financial relationships to disclose.
Lauren Rieck, MBA has no relevant financial relationships to disclose.
Eve Wilson, PhD has no relevant financial relationships to disclose.
Steve E. Lommatzsch, MD discloses he is an investigator for Insmed.

Accreditation and Credit Designation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of National Jewish Health and PlatformQ Health Education. National Jewish Health is accredited by the ACCME to provide continuing medical education for physicians.

National Jewish Health designates each enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.

Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.

Disclaimer

National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.